Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

COMy 2022 | iStopMM study – the impact of nationwide screening

Sigurdur Kristinsson • 12 May 2022
COMy 2022
Multiple Myeloma Rare Diseases Smoldering Myeloma
iStopMM

Sigurdur Kristinsson, MD, PhD, University of Iceland, Reykjavík, Iceland, shares some insights into the iStopMM study (NCT03327597), which is looking at early detection, and therefore early intervention in patients with smoldering multiple myeloma (SMM). The study aims to minimize the incidence of myeloma in Iceland with the hope of treating patients to prevent them from developing myeloma in the future. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.

Disclosures

Gelgene, Amgen

More from Sigurdur Kristinsson

Treating smoldering myeloma and the importance of improving patient selection 1:21
Treating smoldering myeloma and the importance of improving patient selection
Sigurdur Kristinsson • 25 Sep 2024
Key takeaways from the iStopMM trial: screening for MGUS 2:04
Key takeaways from the iStopMM trial: screening for MGUS
Sigurdur Kristinsson • 25 Sep 2024
iStopMM analysis results: autoimmune diseases are not associated with MGUS 2:47
iStopMM analysis results: autoimmune diseases are not associated with MGUS
Sigurdur Kristinsson • 12 Dec 2022
Evaluating whether SARS-CoV-2 vaccination has an impact on risk of progression from MGUS to myeloma 1:51
Evaluating whether SARS-CoV-2 vaccination has an impact on risk of progression from MGUS to myeloma
Sigurdur Kristinsson • 12 Dec 2022

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals